Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A

Pharmaceutical Research

Volumn 23, Issue 7, 2006, Pages 1473-1481

  White, Karen ^a   Rades, Thomas ^a   Kearns, Philip ^b   Toth, Istvan ^b   Hook, Sarah ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

CD8 T cell; Lipid core peptide; Liposome; Quil A; Vaccine

Indexed keywords

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; LIPID; LIPID CORE PEPTIDE; LIPOSOME; MANNOSE; OVALBUMIN; QUIL A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG FORMULATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BONE MARROW CELLS; CANCER VACCINES; CELL PROLIFERATION; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; INJECTIONS, SUBCUTANEOUS; LIPOPROTEINS; LIPOSOMES; MANNOSE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PEPTIDE FRAGMENTS; PHOSPHOLIPIDS; SAPONINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33745614875     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-0272-z     Document Type: Article

References (33)

1. C. Olive M. Batzloff A. Horvath T. Clair P. Yarwood I. Toth M. F. Good 2003 Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens Infect. Immun. 71 2373 2383
2. C. Olive M. Batzloff A. Horvath A. Wong T. Clair P. Yarwood I. Toth M. Good 2002 A lipid core peptide construct containing a conserved region determinant of the group a streptococcal M protein elicits heterologous opsonic antibodies Infect. Immun. 70 2734 2738
3. W. Hayman I. Toth N. Flinn M. Scanlon M. Good 2002 Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology Immunol. Cell Biol. 80 178 187
4. K. White P. Kearns I. Toth S. Hook 2004 Increased adjuvant activity of minimal CD8 T cell peptides incorporated into lipid-core-peptides Immunol. Cell Biol. 82 517 522
5. Y. Zhan A. Corbett J. Brady R. Sutherland A. Lew 2000 CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on co-stimulation J. Immunol. 165 3612 3619
6. B. Wang C. Norbury R. Greenwood J. Bennink J. Yewdell J. Frelinger 2001 Multiple paths for activation of naive CD8(+) T cells: CD4-independent help J. Immunol. 167 1283 1289
7. J. Wang A. Livingstone 2003 Cutting edge: CD4(+) T cell help can be essential for primary CD8(+) T cell responses in vivo J. Immunol. 171 6339 6343
8. A. Kaiser N. Bercovici J. Abastado A. Nardin 2003 Naive CD8(+) T cell recruitment and proliferation are dependent on stage of dendritic cell maturation Eur. J. Immunol. 33 162 171
9. H. Hu H. Winter J. Ma M. Croft W. Urba B. Gox 2002 CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8(+) T cells J. Immunol. 169 4897 4904
10. H. Guan W. Budzynski R. Koganty M. Krantz M. Reddish J. Rogers B. Longenecker J. Samuel 1998 Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses Bioconjug. Chem. 9 451 458
11. I. Fernandes B. Frisch S. Muller F. Schuber 1997 Synthetic lipopeptides incorporated in liposomes: in vitro stimulation of the proliferation of murine splenocytes and in vivo induction of an immune response against a peptide antigen Mol. Immunol. 34 569 576
12. L. Flebbe H. Braley-Mullen 1986 Immunopotentiating effects of the adjuvants SGP and Quil A: I. Antibody responses to T-dependent and T-independent antigens Cell. Immunol. 99 119 127
13. S. Kamstrup R. San Martin A. Doberti H. Grande K. Dalsgaard 2000 Preparation and characterisation of Quillaja saponin with less heterogeneity than Quil-A Vaccine 18 2244 2249
14. M. Baca-Estrada M. Foldvari M. Snider S. van Drunen Littel-vanden Hurk L. Babiuk 1997 Effect of IL-4 and IL-12 liposomal formulations on the induction of immune response to bovine herpes virus type-1 glycoprotein D Vaccine 15 1753 1760
15. A. Ninomiya K. Ogasawara K. Kajino A. Takada H. Kida 2002 Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice Vaccine 20 3123 3129
16. M. van Slooten G. Storm A. Zoephel Z. Kupcu O. Boerman D. Crommelin E. Wagner R. Kircheis 2000 Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines Pharm. Res. 17 42 48
17. M. Jaafari M. Foldvari 2002 Targeting of liposomes to melanoma cells with high levels of ICAM-1 expression through adhesive peptides from immunoglobulin domains J. Pharm. Sci. 91 396 404
18. M. Copland M. Baird T. Rades J. [tmp] McKenzie B. Becker F. Reck P. Tyler N. Davies 2003 Liposomal delivery of antigen to human dendritic cells Vaccine 21 883 890
19. G. Kersten D. Crommelin 1995 Liposomes and ISCOMs as vaccine formulations Biochim. Biophys. Acta 1241 117 138
20. P. Demana N. Davies B. Berger T. Rades 2004 Incorporation of ovalbumin into ISCOMs and related colloidal particles prepared by the lipid film hydration method Int. J. Pharm. 278 263 274
21. L. East C. Isacke 2002 The mannose receptor family Biochim. Biophys. Acta 1572 364 386
22. F. Sallusto A. Lanzavecchia 1994 Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumour necrosis factor α J. Exp. Med. 179 1109 1118
23. K. Mahnke M. Guo S. Lee H. Sepulveda S. Swain M. Nussenzweg R. Steinman 2000 The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments J. Cell Biol. 151 673 683
24. L. Bonifaz D. Bonnyay K. Mahnke M. Rivera M. Nussenzweig R. Steinman 2002 Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance J. Exp. Med. 196 1627 1638
25. P. Demana C. Fehske K. White T. Rades S. Hook 2004 Effect of incorporation of the adjuvant Quil A on structure and immune stimulatory capacity of liposomes Immunol. Cell Biol. 82 547 554
26. M. Moore F. Carbone M. Bevan 1988 Introduction of soluble protein into the class I pathway of antigen processing and presentation Cell 54 777 785
27. A. Agrawal A. Puri W. Haq C. Gupta 2001 Enhanced immunostimulant activity and protective effect of a synthetic lipopeptide after liposomization against Plasmodium berghei infection in mice J. Drug Target. 9 231 239
28. R. New 1990 Liposomes: A Practical Approach Oxford University Press New York
29. M. Steinman D. Hawiger M. C. Nussenzweig 2003 Tolerogenic dendritic cells Annu. Rev. Immunol. 21 685 711
30. C. Kensil 1996 Saponins as vaccine adjuvants Crit. Rev. Ther. Drug Carrier Syst. 13 1 55
31. B. Rönnberg M. Fekadu B. Morein 1995 Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix Vaccine 13 1375 1382
32. G. Lipford H. Wagner K. Heeg 1994 Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T-cells Vaccine 12 73 80
33. S. Behboudi B. Morein M. Villacres-Eriksson 1996 In vitro activation of antigen-presenting cells (APC) by defined composition of Quillaja saponaria Molina triterpenoids Clin. Exp. Immunol. 105 26 30